Cytokinetics eyes expanded use of heart drug after promising late-stage data
By Bhanvi Satija and Mariam Sunny Aug 28 (Reuters) – Cytokinetics said on Friday detailed late-stage data showed its drug, aficamten, significantly improved symptoms and exercise capacity in patients with a genetic heart condition that currently has no approved treatments. The results, presented at

























